Tag - FDA

COVID-19 – Viral Vector Versus mRNA Vaccines

Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide

Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

QIAGEN announces Digital Partner Program with five initial partnerships

Personal Genome Diagnostics Announces Close of $103 Million Series C Financing

23andMe to Merge with Virgin Group’s VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics

Personal Genome Diagnostics and QIAGEN Collaborate to Offer Integrated Genomic Testing and Interpretation Support

Helix® Laboratory Platform Granted the First and Only FDA Authorization for a Whole Exome Sequencing Platform

2020 Was Not Just About COVID-19

Everlywell Announces $175 Million Financing to Expand Consumer Lab Testing and Digital Health Offerings

Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy

Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection

Biofidelity raises $12m in Series A financing to accelerate launch of disruptive cancer diagnostic technology

Syapse and FDA Expand Existing Research Collaboration to Rapidly Generate Real-World Data Related to COVID-19 and Cancer

Helix Receives FDA Emergency Use Authorization for the HelixⓇ COVID-19 NGS Test, One of the First Sequencing-Based COVID-19 Tests

Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

Copyright © 2021 · Created by enlighenbio LLC TM